MartinPLefkowitzMD

Vice-President, Cardiovascular and Renal Therapeutic Area Head, Global Clinical Development, Novartis Pharmaceuticals

Dr. Lefkowitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

102 citations
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF
Craig Balmforth, Joanne Simpson, Li Shen, Pardeep S. Jhund, Martin Lefkowitz
JACC. Heart Failure. 2019-06-01
148 citations
B-TYPE NATRIURETIC PEPTIDE DURING TREATMENT WITH SACUBITRIL/VALSARTAN: THE PARADIGM-HF TRIAL
Peder L. Myhre, Muthiah Vaduganathan, Brian Claggett, Milton Packer, Akshay S. Desai
Journal of the American College of Cardiology. 2019-03-26
40 citations
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
James L. Januzzi, Milton Packer, Brian Claggett, Jiankang Liu, Amil M. Shah
Circulation. Heart Failure. 2018-10-01

Journal Articles

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients with Heart Failure
Milton Packer, Alvin Chandra, Akshay S. Desai, Martin P Lefkowitz, Martin P. Lefkowitz, Milton Packer, Michael R. Zile, Scot D. Solomon, Michael R Zile, Alvin Chandra,..., JAMA
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
Michael R Zile, Martin P Lefkowitz, Scott D Solomon, Milton Packer, Akshay S Desai, ScienceDirect